Hoechst Products to Be Boycotted In The USA

17 July 1994

Protesters in the USA against the launch in the country of the abortificient Mifegyne (mifepristone; aka RU 486) have identified products that are to be targeted for boycott by its supporters. The protesters have formed a coalition antiabortion group to focus their efforts.

Drugs to be boycotted that are manufactured by Hoechst Roussel include antiacne solution ATS (erythromycin) the antihypertensiv Altace (ramipril), the anti-infective Claforan (cefotaxime sodium), Lasix (ciclopirox) used to treat skin infections, Prokine (sargramostim), a white cell growth factor, and Topicort (desoximetasone), used to treat skin rashes.

Also on the boycott list are the following drugs from Copley: the decongestant antihistamine Bromatapp (brompheniramine maleate, phenylephrine HCl and phenylpropanolamine HCl), the sedative doxylamine succinate, the topical antifungal miconazole nitrate, and tolnaftate a solution for fungal skin infections.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight